Samara Perez1, Ovidiu Tatar2, Vladimir Gilca3, Gilla K Shapiro4, Gina Ogilvie5, Juliet Guichon6, Anila Naz7, Zeev Rosberger8. 1. Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec H3A 1B1, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada. Electronic address: samara.perez@mail.mcgill.ca. 2. Lady Davis Institute for Medical Research, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada. Electronic address: ovidiu.tatar@mail.mcgill.ca. 3. Institut National de Santé Publique du Québec, 945 Wolfe Avenue, Québec, Quebec G1V 5B3, Canada. Electronic address: vladimir.gilca@inspq.qc.ca. 4. Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec H3A 1B1, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada. Electronic address: gilla.shapiro@mail.mcgill.ca. 5. Faculty of Medicine, University of British Columbia, BC Women's Hospital and Health Centre, Room H203G, 4500 Oak Street, Vancouver, British Columbia V6H 3N1, Canada. Electronic address: gina.ogilvie@bccdc.ca. 6. Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive N.W., Calgary, Alberta T2N 4N1, Canada. Electronic address: guichon@ucalgary.ca. 7. Lady Davis Institute for Medical Research, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada. Electronic address: anila.naz@mail.mcgill.ca. 8. Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec H3A 1B1, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada; Louise Granofsky-Psychosocial Oncology Program, Segal Cancer Center, Jewish General Hospital, 4333 Cote Ste-Catherine Road, Montreal, Quebec H3T 1E4, Canada. Electronic address: zeev.rosberger@mcgill.ca.
Abstract
BACKGROUND: HPV vaccination uptake in boys is suboptimal in many jurisdictions, particularly in the absence of publicly funded HPV vaccination programs. Parents represent key decision-makers of HPV vaccination and their HPV vaccine decision-making stage is influenced by multiple psychosocial determinants. Our objective was to assess the relationship between a broad range of psychosocial factors and parents of boys' HPV vaccine decision-making stage. METHODS: Data were collected through an online survey from a nationally representative sample of Canadian parents of boys in February (T1) and November 2014 (T2). We assessed a broad number of psychosocial factors including: socio-demographics, health behaviours and validated scales for assessing HPV knowledge, attitudes and beliefs. Parents selected their HPV vaccination adoption stage based on the Precaution Adoption Process Model (PAPM). Multinomial logistic regression was used to test the association between predictors and PAPM stage at T1 and T2. RESULTS: Discussion with a healthcare provider about the HPV vaccine and increased HPV knowledge was associated with increased odds of being in the more advanced PAPM stages. Increased perception of risks in the absence of HPV vaccination, increased perception that others endorse HPV vaccination and positive attitudes related to vaccines in general were associated with increased odds of being in the decided to vaccinate stage. Believing that HPV vaccination is harmful increased, and perceiving the benefits of HPV vaccination decreased the odds of deciding not to vaccinate. CONCLUSIONS: This study highlights the psychosocial predictors of the decision-making stage reported by parents regarding HPV vaccination of their sons, that were significant at two time-points. Targeted interventions that consider the impact of the health care provider and address knowledge gaps as well as individual beliefs about benefits, risks, and harms of the HPV vaccine and vaccines in general should be implemented to help parents make better informed decisions that is, to move closer to actual vaccination adoption.
BACKGROUND: HPV vaccination uptake in boys is suboptimal in many jurisdictions, particularly in the absence of publicly funded HPV vaccination programs. Parents represent key decision-makers of HPV vaccination and their HPV vaccine decision-making stage is influenced by multiple psychosocial determinants. Our objective was to assess the relationship between a broad range of psychosocial factors and parents of boys' HPV vaccine decision-making stage. METHODS: Data were collected through an online survey from a nationally representative sample of Canadian parents of boys in February (T1) and November 2014 (T2). We assessed a broad number of psychosocial factors including: socio-demographics, health behaviours and validated scales for assessing HPV knowledge, attitudes and beliefs. Parents selected their HPV vaccination adoption stage based on the Precaution Adoption Process Model (PAPM). Multinomial logistic regression was used to test the association between predictors and PAPM stage at T1 and T2. RESULTS: Discussion with a healthcare provider about the HPV vaccine and increased HPV knowledge was associated with increased odds of being in the more advanced PAPM stages. Increased perception of risks in the absence of HPV vaccination, increased perception that others endorse HPV vaccination and positive attitudes related to vaccines in general were associated with increased odds of being in the decided to vaccinate stage. Believing that HPV vaccination is harmful increased, and perceiving the benefits of HPV vaccination decreased the odds of deciding not to vaccinate. CONCLUSIONS: This study highlights the psychosocial predictors of the decision-making stage reported by parents regarding HPV vaccination of their sons, that were significant at two time-points. Targeted interventions that consider the impact of the health care provider and address knowledge gaps as well as individual beliefs about benefits, risks, and harms of the HPV vaccine and vaccines in general should be implemented to help parents make better informed decisions that is, to move closer to actual vaccination adoption.
Authors: R Grewal; S L Deeks; T A Hart; J Cox; A De Pokomandy; T Grennan; G Lambert; D Moore; F Coutlée; M Gaspar; C George; D Grace; J Jollimore; N J Lachowsky; R Nisenbaum; G Ogilvie; C Sauvageau; D H S Tan; A Yeung; A N Burchell Journal: Hum Vaccin Immunother Date: 2021-12-02 Impact factor: 3.452
Authors: Gabrielle Griffin-Mathieu; Ben Haward; Ovidiu Tatar; Patricia Zhu; Samara Perez; Gilla K Shapiro; Emily McBride; Erika L Thompson; Laurie W Smith; Aisha K Lofters; Ellen M Daley; Juliet R Guichon; Jo Waller; Marc Steben; Kathleen M Decker; Marie-Helene Mayrand; Julia M L Brotherton; Gina S Ogilvie; Gregory D Zimet; Teresa Norris; Zeev Rosberger Journal: JMIR Res Protoc Date: 2022-06-16
Authors: Sayward E Harrison; Valerie Yelverton; Yunfei Wang; Jan Ostermann; Laura J Fish; Charnetta L Williams; Lavanya Vasudevan; Emmanuel B Walter Journal: Am J Health Behav Date: 2021-09-30
Authors: Laura M Kiener; Corina L Schwendener; Kristen Jafflin; Audrey Meier; Noah Reber; Susanna Schärli Maurer; Franco Muggli; Nejla Gültekin; Benedikt M Huber; Sonja Merten; Michael J Deml; Philip E Tarr Journal: BMJ Open Date: 2022-04-21 Impact factor: 3.006